Last reviewed · How we verify
Silicified microcrystalline cellulose
Silicified microcrystalline cellulose is an inert pharmaceutical excipient that acts as a binder and flow agent in tablet formulations.
At a glance
| Generic name | Silicified microcrystalline cellulose |
|---|---|
| Also known as | Placebo |
| Sponsor | ZS Pharma, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
This is not an active pharmaceutical ingredient but rather a structural component used in drug manufacturing. It improves tablet hardness, flow properties, and stability by providing mechanical support and reducing moisture absorption. It is commonly used as a filler and binder in oral solid dosage forms.
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- A Clinical Trial to Investigate the Safety and Efficacy of AP-Brain on Cognitive Function at Varying Dosages in Healthy Younger Adults With Self-reported Attention Problems (NA)
- A Clinical Trial to Investigate the Safety and Efficacy of AP-Brain on Cognitive Function at Varying Dosages in Healthy Middle-aged and Older Adults With Self-reported Memory Problems (NA)
- Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults (PHASE3)
- Antecedent Metabolic Health and Metformin Aging Study (PHASE3)
- Evaluating the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 in Healthy Adult Participants (PHASE1)
- Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease (PHASE2)
- A Randomized Phase 1 of of MZE001 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Silicified microcrystalline cellulose CI brief — competitive landscape report
- Silicified microcrystalline cellulose updates RSS · CI watch RSS
- ZS Pharma, Inc. portfolio CI